ClinicalTrials.gg
CompletedNCT00422240Updated Apr 15, 2024Results posted

Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

A Phase 3 interventional study of Adapalene/Benzoyl Peroxide and Adapalene Gel, 0.1% in Acne Vulgaris, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2006, registered Jan 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,668
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing adapalene in Acne Vulgaris — none open to participants now, 2 under way, none of them phase 3. Adapalene · Acne Vulgaris.

Enrollment
2nd of 30
1,668 · median 215
Started
2006
with 1 other
Phase 3
9 of 30
none open now
Registered
2nd of 30
by date
Lead sponsor
10 of 30
Galderma R&D

Among the 30 studies testing adapalene in Acne Vulgaris, this one is the 2nd largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 2nd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 30 studies testing adapalene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About adapalene

Adapalene: first FDA approval 1996 (DIFFERIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing adapalene in Acne Vulgaris as a file.
02

Study summary

This was a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations were performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a participant should remain the same during the study.

The primary objective was to demonstrate the superiority in efficacy and assess safety of adapalene/benzoyl peroxide topical gel (adapalene/benzoyl peroxide gel) versus adapalene topical gel, 0.1% (adapalene monad); benzoyl peroxide topical gel, 2.5% (benzoyl peroxide monad) and topical gel vehicle (gel vehicle) in the treatment of acne vulgaris for up to 12 weeks.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne vulgaris
  • Adapalene
  • Benzoyl Peroxide
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • A clinical diagnosis of acne vulgaris with facial involvement.
  • A minimum of 20 but not more than 50 inflammatory lesions
  • A minimum of 30 but not more than 100 noninflammatory lesions
  • A score of 3 (Moderate) on the Investigator's Global Assessment Scale
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,668 participants (actual)

Study arms

  • Experimental
    Adapalene/Benzoyl Peroxide Gel

    Participants were treated with adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.

    Drug: Adapalene/Benzoyl Peroxide

  • Experimental
    Adapalene Gel, 0.1%

    Participants were treated with 0.1% of adapalene gel topically daily in the evening for 12 Weeks.

    Drug: Adapalene Gel, 0.1%

  • Experimental
    Benzoyl Peroxide Gel 2.5%

    Participants were treated with 2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.

    Drug: Benzoyl Peroxide Gel 2.5%

  • Placebo comparator
    Gel Vehicle

    Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.

    Drug: Gel Vehicle

Interventions

  • DrugAdapalene/Benzoyl Peroxide

    Drug pages: Adapalene · Benzoyl Peroxide

    Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.

  • DrugAdapalene Gel, 0.1%

    0.1% of adapalene gel topically daily in the evening for 12 Weeks.

  • 2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.

  • DrugGel Vehicle

    Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward)

    Success rate was defined as percentage of participants who achieved "Clear" or "Almost Clear" score on the IGA scale. IGA scale consisted of 5 grades (0-4) among which 0 = Clear (Minor, residual discoloration, no erythema or induration/papulation, no oozing/crusting), 1 = Almost clear (Trace, faint pink erythema with almost no induration/papulation and no oozing/crusting), 2 = Mild (Faint pink erythema with mild induration/papulation and no oozing/crusting), 3 = Moderate (Pink-red erythema with moderate induration/papulation and there may be some oozing/crusting.), 4 = Severe (Deep/bright red erythema with severe induration/papulation with oozing/crusting). All missing values were imputed by LOCF.

    Time frame: At Week 12

  2. Change in Inflammatory Lesion Count From Baseline to Week 12

    Change in inflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.

    Time frame: Baseline to Week 12

  3. Change in Noninflammatory Lesion Count From Baseline to Week 12

    Change in noninflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percent Change From Baseline in Inflammatory Lesion Counts at Week 12

    The Inflammatory Lesion Count was the sum of papules and pustules. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.

    Time frame: Baseline, Week 12

  2. Percent Change From Baseline in Noninflammatory Lesion Counts at Week 12

    The Noninflammatory Lesion Count was the sum of open comedones and closed comedones. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.

    Time frame: Baseline, Week 12

  3. Percent Change From Baseline in Total Lesion Counts at Week 12

    The Total Lesion Count was the sum of Inflammatory, Noninflammatory Lesion Counts, Nodules and Cysts.

    Time frame: Baseline, Week 12

07

Results

Posted Apr 15, 2024

Participant flow

Participant flow — Overall Study
MilestoneAdapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel Vehicle
Started415420415418
Completed347363372347
Not completed68574371
Withdrew: Lack of efficacy1201
Withdrew: Adverse event11452
Withdrew: Subject request21171830
Withdrew: Protocol violation0101
Withdrew: Lost to follow-up31321934
Withdrew: Other1001
Withdrew: Pregnancy3112

Outcome measures

PrimaryPercentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward)

Success rate was defined as percentage of participants who achieved "Clear" or "Almost Clear" score on the IGA scale. IGA scale consisted of 5 grades (0-4) among which 0 = Clear (Minor, residual discoloration, no erythema or induration/papulation, no oozing/crusting), 1 = Almost clear (Trace, faint pink erythema with almost no induration/papulation and no oozing/crusting), 2 = Mild (Faint pink erythema with mild induration/papulation and no oozing/crusting), 3 = Moderate (Pink-red erythema with moderate induration/papulation and there may be some oozing/crusting.), 4 = Severe (Deep/bright red erythema with severe induration/papulation with oozing/crusting). All missing values were imputed by LOCF.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward)
percentage of participantsAdapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel Vehicle
Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried Forward)30.119.822.211.3
PrimaryChange in Inflammatory Lesion Count From Baseline to Week 12

Change in inflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.

Time frame:
Baseline to Week 12
Reported as:
Median · lesions
Change in Inflammatory Lesion Count From Baseline to Week 12
lesionsAdapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel Vehicle
Baseline27.0 (23 to 35)27.0 (23 to 34)27.0 (23 to 34)27.0 (22 to 35)
Change at Week 12-16.0 (-22 to -10)-14.0 (-20 to -7)-16.0 (-21 to -7)-10.0 (-16 to -2)
PrimaryChange in Noninflammatory Lesion Count From Baseline to Week 12

Change in noninflammatory lesion count from baseline to week 12 was reported. All missing values were imputed by LOCF.

Time frame:
Baseline to Week 12
Reported as:
Median · lesions
Change in Noninflammatory Lesion Count From Baseline to Week 12
lesionsAdapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel Vehicle
Baseline44.0 (36 to 62)47.0 (37 to 61)46.0 (36 to 63)46.0 (36 to 62)
Change at Week 12-24.0 (-35 to -13)-22.0 (-34 to -11)-20.0 (-32 to -7)-14.0 (-25 to -1)
SecondaryPercent Change From Baseline in Inflammatory Lesion Counts at Week 12

The Inflammatory Lesion Count was the sum of papules and pustules. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Inflammatory Lesion Counts at Week 12
percent changeAdapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel Vehicle
Percent Change From Baseline in Inflammatory Lesion Counts at Week 12-55.33 ± 34.678-41.68 ± 41.855-47.61 ± 38.415-30.23 ± 41.661
SecondaryPercent Change From Baseline in Noninflammatory Lesion Counts at Week 12

The Noninflammatory Lesion Count was the sum of open comedones and closed comedones. Percent change from Baseline was calculated as the values at Week 12 minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Noninflammatory Lesion Counts at Week 12
percent changeAdapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel Vehicle
Percent Change From Baseline in Noninflammatory Lesion Counts at Week 12-48.15 ± 35.428-40.75 ± 40.822-37.23 ± 39.758-23.22 ± 48.613
SecondaryPercent Change From Baseline in Total Lesion Counts at Week 12

The Total Lesion Count was the sum of Inflammatory, Noninflammatory Lesion Counts, Nodules and Cysts.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change in lesions
Percent Change From Baseline in Total Lesion Counts at Week 12
percent change in lesionsAdapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel Vehicle
Percent Change From Baseline in Total Lesion Counts at Week 12-49.97 ± 31.966-41.29 ± 36.133-41.23 ± 33.794-26.06 ± 38.714

Adverse events

Collected over From start of the study drug administration up to Week 12.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adapalene/Benzoyl Peroxide Gel0/415 (0%)2/415 (0.5%)44/415 (10.6%)
Adapalene Gel, 0.1%0/420 (0%)3/420 (0.7%)51/420 (12.1%)
Benzoyl Peroxide Gel 2.5%0/415 (0%)0/415 (0%)29/415 (7%)
Gel Vehicle0/418 (0%)1/418 (0.2%)34/418 (8.1%)
Most frequent serious events
Most frequent serious events
EventAdapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel Vehicle
DepressionPsychiatric disorders1/4151/4200/4150/418
Suicide attemptPsychiatric disorders1/4150/4200/4150/418
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/4150/4200/4151/418
Affective disorderPsychiatric disorders0/4151/4200/4150/418
AbscessInfections and infestations0/4151/4200/4150/418
Cellulitis staphylococcalInfections and infestations0/4151/4200/4150/418
Most frequent other events
Most frequent other events
EventAdapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel Vehicle
NasopharyngitisInfections and infestations16/41530/42020/41521/418
Dry skinSkin and subcutaneous tissue disorders28/41521/4209/41513/418

Baseline characteristics

ITT (Intent-to-Treat) Population included all treated participants.

Age, Continuous
Age, Continuous(years)Adapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel VehicleTotal
Mean18.7 ± 7.1417.9 ± 5.4018.4 ± 6.5518.0 ± 6.0918.2 ± 6.33
Sex: Female, Male
Sex: Female, Male(Participants)Adapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel VehicleTotal
Female210217207222856
Male205203208196812
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Adapalene/Benzoyl Peroxide GelAdapalene Gel, 0.1%Benzoyl Peroxide Gel 2.5%Gel VehicleTotal
Caucasian2732812582701082
Black66648166277
Asian444517
Hispanic67666572270
Other557522
08

Study locations

1 site
  • Miller MD
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003 Sep;49(3 Suppl):S200-10. doi: 10.1067/s0190-9622(03)01154-x. PubMed 12963896 ↗
  • Gold LS, Tan J, Cruz-Santana A, Papp K, Poulin Y, Schlessinger J, Gidner J, Liu Y, Graeber M; Adapalene-BPO Study Group. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009 Aug;84(2):110-6. PubMed 19746769 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2006 to primary completion in Jul 2007, 12 months.

Results were first posted in Apr 2024, 16 years 9 months after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 12 months is close to that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2007
First posted
Jan 15, 2007
StartActual
Jun 27, 2006
Primary completionActual
Jul 12, 2007
CompletionActual
Jul 12, 2007
Results first posted
Apr 15, 2024
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00422240
Lead sponsor
Galderma R&D
First posted
Jan 15, 2007
Start date
Jun 27, 2006
Primary completion
Jul 12, 2007
Completion
Jul 12, 2007
Results posted
Apr 15, 2024
Last update
Apr 15, 2024

Study contacts

Michael Graeber, MD
study director · Galderma R&D
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adapalene · Benzoyl Peroxide

Start the discussion